Subcutaneous panniculitic-like T-cell lymphoma localized to a site of peginterferon alfa-2a administration

References

• Aronson IK, West DP, Variakojis D, et al. Fatal panniculitis. J Am Acad Dermatol. 1985;12(3):535–551. doi:10.1016/s0190-9622(85)70076-x
   PubMed Web of Science ®Google Scholar
• Magro CM, Crowson AN, Kovatich AJ, et al. Lupus profundus, indeterminate lymphocytic lobular panniculitis and subcutaneous T-cell lymphoma: a spectrum of subcuticular T-cell lymphoid dyscrasia. J Cutan Pathol. 2001;28(5):235–247. doi:10.1034/j.1600-0560.2001.028005235.x
   PubMed Web of Science ®Google Scholar
• von Dücker L, Fleischer M, Stutz N, et al. Primary cutaneous gamma-Delta T-cell lymphoma with long-Term indolent clinical course initially mimicking lupus erythematosus profundus. Front Oncol. 2020;10:133. doi:10.3389/fonc.2020.00133
   PubMed Web of Science ®Google Scholar
• Aguilera P, Mascaró JM, Jr, Martinez A, et al. Cutaneous gamma/Delta T-cell lymphoma: a histopathologic mimicker of lupus erythematosus profundus (lupus panniculitis). J Am Acad Dermatol. 2007;56(4):643–647. doi:10.1016/j.jaad.2006.08.029
   PubMed Web of Science ®Google Scholar
• Bosisio F, Boi S, Caputo V, et al. Lobular panniculitic infiltrates with overlapping histopathologic features of lupus panniculitis (lupus profundus) and subcutaneous T-cell lymphoma: a conceptual and practical dilemma. Am J Surg Pathol. 2015;39(2):206–211. doi:10.1097/PAS.0000000000000307
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Mitsui A, Noda K, et al. Subcutaneous panniculitis-like T-cell lymphoma with a HAVCR2 mutation diagnosed after 10 years of treatment with glucocorticoids and cyclosporine as lupus panniculitis. Intern Med. 2023;62(10):1537–1540. doi:10.2169/internalmedicine.0428-22
   PubMed Web of Science ®Google Scholar
• Arrabaca RA. TCL-084 subcutaneous panniculitis-like T-cell lymphoma with Co-Existing lupus panniculitis: a case report. Clin Lymphoma Myeloma Leuk. 2022;22Suppl(2):S396. doi:10.1016/S2152-2650(22)01572-5
   Google Scholar
• Machan S, Rodríguez M, Alonso-Alonso R, et al. Subcutaneous panniculitis-like T-cell lymphoma, lupus erythematosus profundus, and overlapping cases: molecular characterization through the study of 208 genes. Leuk Lymphoma. 2021;62(9):2130–2140. doi:10.1080/10428194.2021.1901098
   PubMed Web of Science ®Google Scholar
• Wu X, Subtil A, Craiglow B, et al. The coexistence of lupus erythematosus panniculitis and subcutaneous panniculitis-like T-cell lymphoma in the same patient. JAAD Case Rep. 2018;4(2):179–184. doi:10.1016/j.jdcr.2017.08.021
   PubMedGoogle Scholar
• Wang X, Magro CM. Human myxovirus resistance protein 1 (MxA) as a useful marker in the differential diagnosis of subcutaneous lymphoma vs. lupus erythematosus profundus. Eur J Dermatol. 2012;22(5):629–633. doi:10.1684/ejd.2012.1790
   PubMed Web of Science ®Google Scholar
• Vermeer MH, Geelen FA, Kummer JA, et al. Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. Am J Pathol. 1999;154(4):1203–1210. doi:10.1016/S0002-9440(10)65372-2
   PubMed Web of Science ®Google Scholar
• Magro CM, Daniels BH, Crowson AN. Drug induced pseudolymphoma. Semin Diagn Pathol. 2018;35(4):247–259. doi:10.1053/j.semdp.2017.11.003
   PubMed Web of Science ®Google Scholar
• Nemoto Y, Taniguchi A, Kamioka M, et al. Epstein-Barr virus-infected subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment. Int J Hematol. 2010;92(2):364–368. doi:10.1007/s12185-010-0642-5
   PubMed Web of Science ®Google Scholar
• Bregman SG, Yeaney GA, Greig BW, et al. Subcutaneous panniculitic T-cell lymphoma in a cardiac allograft recipient. J Cutan Pathol. 2005;32(5):366–370. doi:10.1111/j.0303-6987.2005.00332.x
   PubMed Web of Science ®Google Scholar
• Magro CM, Segal JP, Crowson AN, et al. The phenotypic profile of dermatomyositis and lupus erythematosus: a comparative analysis. J Cutan Pathol. 2010;37(6):659–671. doi:10.1111/j.1600-0560.2009.01443.x
   PubMed Web of Science ®Google Scholar
• Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/Delta subtypes. Am J Surg Pathol. 1998;22(7):881–893. doi:10.1097/00000478-199807000-00010
   PubMed Web of Science ®Google Scholar
• Sitthinamsuwan P, Pattanaprichakul P, Treetipsatit J, et al. Subcutaneous panniculitis-like T-cell lymphoma versus lupus erythematosus panniculitis: distinction by means of the periadipocytic cell proliferation index. Am J Dermatopathol. 2018;40(8):567–574. doi:10.1097/DAD.0000000000001173
   PubMed Web of Science ®Google Scholar
• Magro CM, Kalomeris T, Dillard A. Panniculitic primary cutaneous gamma Delta T-cell lymphoma with concomitant features of autoimmune disease emphasizing a pathophysiologic continuum of lupus profundus with the panniculitic T cell lymphomas. Clin Dermatol. 2023;41(6):680–691. doi:10.1016/j.clindermatol.2023.09.008
   PubMed Web of Science ®Google Scholar
• Koh J, Jang I, Mun S, et al. Genetic profiles of subcutaneous panniculitis-like T-cell lymphoma and clinicopathological impact of HAVCR2 mutations. Blood Adv. 2021;5(20):3919–3930. doi:10.1182/bloodadvances.2021004562
   PubMed Web of Science ®Google Scholar
• Urosevic-Maiwald M, Nobbe S, Kerl K, et al. Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: treatment- or disease-related? J Dermatol. 2014;41(4):329–333. doi:10.1111/1346-8138.12389
   PubMed Web of Science ®Google Scholar
• Nieforth KA, Nadeau R, Patel IH, et al. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther. 1996;59(6):636–646. doi:10.1016/S0009-9236(96)90003-X
   PubMed Web of Science ®Google Scholar
• Noureddin M, Ghany MG. Pharmacokinetics and pharmacodynamics of peginterferon and ribavirin: implications for clinical efficacy in the treatment of chronic hepatitis C. Gastroenterol Clin North Am. 2010;39(3):649–658. doi:10.1016/j.gtc.2010.08.008
   PubMed Web of Science ®Google Scholar
• Foster GR. Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs. 2010;70(2):147–165. doi:10.2165/11531990-000000000-00000
   PubMed Web of Science ®Google Scholar
• Sparsa A, Loustaud-Ratti V, Alain S, et al. Skin necrosis after injection of PEG-interferon alpha2b in an HCV-infected patient. Acta Derm Venereol. 2004;84(5):415–416.
   PubMed Web of Science ®Google Scholar
• Kurzen H, Petzoldt D, Hartschuh W, et al. Cutaneous necrosis after subcutaneous injection of polyethylene-glycol-modified interferon alpha. Acta Derm Venereol. 2002;82(4):310–312. doi:10.1080/000155502320323360
   PubMed Web of Science ®Google Scholar
• Dalmau J, Pimentel CL, Puig L, et al. Cutaneous necrosis after injection of polyethylene glycol-modified interferon alfa. J Am Acad Dermatol. 2005;53(1):62–66. doi:10.1016/j.jaad.2005.02.031
   PubMed Web of Science ®Google Scholar
• Song JS, Sohn JH, Jeong JY, et al. Repeated panniculitis induced by pegylated interferon alpha 2a in a patient with chronic hepatitis C. Korean J Gastroenterol. 2016;67(5):272–276. doi:10.4166/kjg.2016.67.5.272
   PubMedGoogle Scholar
• Hashimoto Y, Kanto H, Itoh M. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus. J Dermatol. 2007;34(8):577–582. doi:10.1111/j.1346-8138.2007.00336.x
   PubMed Web of Science ®Google Scholar
• Toney RC, Agrawal RM, Loeffert M. Injection site bullous eruption and generalized rash induced by pegylated interferon treatment for hepatitis C. Gastroenterol Hepatol (N Y). 2009;5(10):715–718.
   PubMedGoogle Scholar
• Montesu MA, Siddi V, Satta R, et al. Bullous lesions at polyethylene glycol interferon-alpha-2a inoculation site in a hepatitis C virus-infected subject. Acta Derm Venereol. 2007;87(5):433–434. doi:10.2340/00015555-0272
   PubMed Web of Science ®Google Scholar
• Rosina P, Girolomoni G. Cutaneous necrosis complicating the injection of pegylated interferon alpha-2b in a patient with chronic hepatitis C. Acta Dermatovenerol Croat. 2008;16(1):35–37.
   PubMed Web of Science ®Google Scholar
• Gallelli L, Guadagnino V, Caroleo B, et al. Cutaneous ulceration induced by interferon alfa. Ann Pharmacother. 2004;38(1):173–174. doi:10.1345/aph.1D198
   PubMed Web of Science ®Google Scholar
• Baek YS, Kim JY, Choi JE, et al. Pegylated interferon Alpha2a induced panniculitis in patient with chronic hepatitis C. Korean J Dermatol. 2012;50(7):640–643.
   Google Scholar
• Heinzerling L, Dummer R, Wildberger H, et al. Cutaneous ulceration after injection of polyethylene-glycol-modified interferon alpha associated with visual disturbances in a melanoma patient. Dermatology. 2000;201(2):154–157. doi:10.1159/000018461
   PubMed Web of Science ®Google Scholar
• Arrue I, Saiz A, Ortiz-Romero PL, et al. Lupus-like reaction to interferon at the injection site: report of five cases. J Cutan Pathol. 2007;34 Suppl 1:18–21. doi:10.1111/j.1600-0560.2007.00715.x
   PubMed Web of Science ®Google Scholar
• Bessis D, Charron A, Rouzier-Panis R, et al. Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient. Eur J Dermatol. 2002;12(1):99–102.
   PubMed Web of Science ®Google Scholar
• Lodato F, Tame MR, Colecchia A, et al. Systemic lupus erythematosus following virological response to peginterferon alfa-2b in a transplanted patient with chronic hepatitis C recurrence. World J Gastroenterol. 2006;12(26):4253–4255. doi:10.3748/wjg.v12.i26.4253
   PubMed Web of Science ®Google Scholar
• Borg FA, Isenberg DA. Syndromes and complications of interferon therapy. Curr Opin Rheumatol. 2007;19(1):61–66. doi:10.1097/BOR.0b013e328010c547
   PubMed Web of Science ®Google Scholar
• Oishi A, Miyamoto K, Kashii S, et al. Retinopathy is not the only ocular symptom: myasthenia gravis in association with interferon therapy. Br J Ophthalmol. 2005;89(11):1542–1543. doi:10.1136/bjo.2005.077537
   PubMed Web of Science ®Google Scholar